BCL2L2 and ovarian carcinoma: This finding confirms that miR‐335‐5p may enhance cisplatin sensitivity of ovarian cancer cells by targeting BCL2L2, which not only provides a promising therapeutic target for the treatment of cisplatin‐resistant ovarian cancer, but proposes a new approach to alleviate cisplatin resistance and reduce ovarian cancer recurrence rate.